Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan

Complete title: NANT 2012-01 PHASE I STUDY OF DIFLUOROMETHYLORNITHINE (DFMO) AND CELECOXIB WITH CYCLOPHOSPHAMIDE/TOPOTECAN FOR PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA

Research Study Number NANT 2012-01
 
Principal Investigator Navin Pinto, MD
 
Phase I

Research Study Description

This study will combine an oral drug called DFMO with celecoxib (also oral) and two IV chemotherapy medicines called cyclophosphamide and topotecan.

- To find the highest dose of DFMO that can be given with celecoxib, cyclophosphamide and topotecan without causing severe side effects.

- To find out the side effects seen by giving DFMO at different dose levels with celecoxib, cyclophosphamide and topotecan.

- To measure the levels of DFMO in the blood at different dose levels.

- To determine if your tumor gets smaller after treatment with DFMO, celecoxib, cyclophosphamide and topotecan.

- To determine if specific gene changes in you or your tumor makes you more prone to side effects or affects your tumor's response to the combination of DFMO, celecoxib, cyclophosphamide and topotecan.

- To determine if the amount of normal chemicals in your body called polyamines go down in response to DFMO, celecoxib, cyclophosphamide and topotecan, and whether you are more likely to have a good response to the treatment if they do.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number NANT 2012-01
 
Contact Advanced Therapeutics Study Line
 
Telephone 206/987-2553
 
E-mail
 

Keywords: Pediatric Cancers, Miscellaneous; Neuroblastoma; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials